"Methylation Markers For The Treatment Of Glioblastoma And Other Cancers" in Patent Application Approval Process (USPTO 20240229155).

A patent application has been filed for a method of treating cancer, specifically glioblastoma and other cancers, by monitoring the methylation status of the STING promoter in tumor cells. If the promoter is found to be methylated, a demethylating agent can be administered to the patient. Conversely, if the promoter is unmethylated, immunotherapy can be administered. The method aims to improve treatment outcomes by increasing or normalizing STING expression and function. The patent application provides detailed claims and methods for predicting responsiveness to immunotherapy and identifying agents that modulate the methylation pattern of STING-silenced tumors. [Extracted from the article]